List of Excipients in Branded Drug EVOTAZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CELLULOSE, MICROCRYSTALLINE	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CROSCARMELLOSE SODIUM	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	CROSPOVIDONE	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	HYDROXYPROPYL CELLULOSE	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	MAGNESIUM STEARATE	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	SILICON DIOXIDE	2032-10-06
ER Squibb & Sons LLC	EVOTAZ	atazanavir and cobicistat	0003-3641	SODIUM STARCH GLYCOLATE TYPE A POTATO	2032-10-06

Excipient Strategy and Commercial Opportunities for EVOTAZ

Last updated: February 26, 2026

What is EVOTAZ?

EVOTAZ is a fixed-dose combination drug used in HIV treatment, containing atazanavir (ATZ) and cobicistat (COBI). Approved by the FDA in 2014, it offers an alternative to regimens requiring separate administration of components, aiming to improve adherence and compliance.

What are the Key Excipient Components in EVOTAZ?

EVOTAZ’s formulation involves excipients supporting stability, solubility, and bioavailability. Major excipients include:

• Microcrystalline cellulose: Tablet binder
• Croscarmellose sodium: Disintegrant
• Magnesium stearate: Lubricant
• Hypromellose (HPMC): Coating agent and controlled-release matrix
• Titanium dioxide: Opacifier
• Some formulations incorporate polyethyleneglycols (PEGs) for solubilization

Exact excipient proportions are proprietary but follow standard practices for HIV drugs with poorly soluble active ingredients.

Excipient Strategy for EVOTAZ

1. Enhancing Solubility and Dissolution

The APIs, atazanavir and cobicistat, exhibit low water solubility. The formulation employs hydrophilic excipients like hypromellose and PEGs to enhance dissolution. Croscarmellose sodium facilitates rapid tablet disintegration, boosting bioavailability.

2. Stability and Shelf-Life

Titanium dioxide and hypromellose contribute to physical integrity and stability, protecting active ingredients from moisture and light. Their use is aligned with regulatory guidelines for drug stability.

3. Manufacturing Considerations

Use of excipients like microcrystalline cellulose and magnesium stearate simplifies scale-up and provides consistent tablet compression. Excipient compatibility with APIs ensures uniformity and reproducibility.

Commercial Opportunities via Excipient Innovation

1. Bioavailability Enhancement

Developing novel solubilizing excipients or disintegrants could improve bioavailability, allowing lower API doses, reducing production costs, and extending patent exclusivity.

2. Formulation Flexibility

Introducing controlled-release or taste-masked formulations through innovative excipients may expand EVOTAZ’s market to pediatric or sensitive populations, increasing patient adherence.

3. Stability and Shelf-Life Extension

Incorporating advanced moisture scavengers or protective excipients can extend shelf life in tropical markets, expanding distribution channels.

4. Differentiation in Manufacturing

Partnerships with excipient suppliers offering high-purity, validated excipients can reduce regulatory hurdles, speed up time to market, and create product differentiation.

5. Customization for Regional Markets

Localized formulations with region-specific excipients can address climatic challenges (humidity, temperature), reducing cold chain reliance and distribution costs.

Regulatory and Supply Chain Considerations

• Use of excipients must align with regulatory standards (e.g., FDA, EMA).
• Suppliers of excipients should have Good Manufacturing Practices (GMP) certification.
• Patent considerations include excipient-related formulation patents and their expiration timelines.

Market Potential and Competitive Landscape

• The HIV drug market is projected to reach USD 35 billion by 2027, growing at 3.9% annually [1].
• Fixed-dose combinations (FDCs) like EVOTAZ hold about 70% of the HIV medication market share [2].
• Innovation in excipient technology can lead to patent extensions or new product launches, capturing more market share.

Strategic Recommendations

• Focus on R&D to innovate excipients enhancing bioavailability or stability.
• Build partnerships with excipient manufacturers for supply chain security.
• Explore formulation modifications targeting pediatric or resistant HIV strains.
• Invest in stability testing to extend shelf life for tropical markets.

Key Takeaways

• Excipient choice in EVOTAZ supports solubility, stability, and manufacturability.
• Innovation in excipients can improve bioavailability, stability, and patient adherence, leading to new commercial opportunities.
• Market growth in fixed-dose HIV therapies sustains the potential for formulation innovation.
• Regulatory compliance and supply chain reliability underpin successful commercialization of excipient strategies.

FAQs

1. Can excipient innovation extend EVOTAZ's patent life?
Yes, reformulating with novel excipients can create new patent opportunities, delaying generic competition.

2. What excipient challenges exist in HIV fixed-dose formulations?
Achieving sufficient solubility, stability, and minimizing side effects are primary concerns.

3. Are there risks using new excipients in EVOTAZ?
Regulatory approval may be more complex, as safety profiles must be well established for new excipients.

4. How do excipient strategies differ between markets?
Regional climate, infrastructure, and regulatory standards influence excipient selection and formulation approaches.

5. What future trends could impact EVOTAZ excipient strategies?
Advances in nanotechnology and bioavailability-enhancing excipients could influence future formulations.

---

References

[1] MarketsandMarkets. (2022). HIV diagnostics and therapy market analysis.

[2] IQVIA. (2021). Global HIV market share report.